Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.
Saved in:
| Title: | Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial. |
|---|---|
| Authors: | Martínez E; Department of Infectious Diseases, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Reial Acadèmia de Medicina de Catalunya, Barcelona, Spain. Electronic address: estebanm@clinic.cat., Watanabe M; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA., Hoffman R; Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Zanni MV; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Pozniak A; Chelsea and Westminster Hospital and London School of Hygiene & Tropical Medicine, London, UK., Shakil SS; Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA., McCallum S; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Chu SM; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Srinivasa S; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Malvestutto CD; Division of Infectious Diseases, Ohio State University Medical Center, Columbus, OH, USA., Fichtenbaum CJ; Division of Infectious Diseases, Department of Medicine, University of Cincinnati, Cincinnati, OH, USA., Bloomfield GS; Department of Medicine, Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, NC, USA., Sponseller CA; Kowa Pharmaceuticals America, Montgomery, AL, USA., Lu AB; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Lu MT; Cardiovascular Imaging Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Aberg JA; Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Currier JS; Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Douglas PS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Ribaudo HJ; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA., Grinspoon SK; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. |
| Corporate Authors: | REPRIEVE Investigators |
| Source: | The lancet. HIV [Lancet HIV] 2026 May; Vol. 13 (5), pp. e327-e337. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
